Cas:2189-60-8 Octylbenzene manufacturer & supplier

Chemical Name:Octylbenzene

CAS.NO:2189-60-8

Synonyms:n-Octylbenzene;Octane,1-phenyl;octyl-benzene;1-Phenyloctane;Benzene, octyl-;n-octyl benzene;Benzene,octyl;n-phenyloctane;1-Octylbenzene;EINECS 218-582-1;8R;Phenyloctane;MFCD00009564;Octylbenzene

Molecular Formula:C₁₄H₂₂

Molecular Weight:190.324

HS Code:2902909090

Physical and Chemical Properties:

Melting point:−36 °C(lit.)

Boiling point:264.5±3.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.487

PSA:

Exact Mass:190.172150

LogP:6.40

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like n-Octylbenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Octylbenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Phenyloctane Use and application,n-phenyloctane technical grade,usp/ep/jp grade.

Related News: Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China. Octylbenzene manufacturer The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. Octylbenzene supplier The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo. Octylbenzene vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. Octylbenzene factory This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care.